La vendita allo scoperto per NMB Finl dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NMB Finl. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NMB Finl (OTC:NMBF) Azioni, Report sulle vendite allo scoperto

NMB Finl Corp is a bank holding company of New Millennium Bank. The bank generates commercial, mortgage, and consumer loans and receives deposits from customers at its New Brunswick and Somerset New Jersey locations. In addition, it also offers various other online banking services.

NMB Finl Corp

WIIM

TOVX

Theriva Biologics shares are trading higher after the company announced it was selected as a finalist for Merck KGaA's EMEA Advance Biotech Grant.

GSAT

Globalstar shares are trading higher after the company amended its services agreement with Apple to launch an extended MSS network with new satellites and infrastructure.

Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) has a Gaudi problem on its hands – the chipmaker revealed that its AI accelerator won't even make $500 million in 2024, falling short of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41685301/analyst-throws-support-behind-intel-ceo-gelsinger-after-better-than-expected-q3-res">CEO Pat Gelsinger's target</a> of $1 billion to $2 billion.
What Happened: Gelsinger revealed during Intel's third-quarter earnings call that the Gaudi AI accelerator program will fall short of revenue targets due to a transition from second to third generation.
"The overall uptake of Gaudi has been slower than we anticipated as adoption rates were impacted by the product transition from Gaudi 2 to Gaudi 3 and software ease of use," Gelsinger said.
"As a result, we will not achieve our target of 500 million in revenue for Gaudi in 2024. That said, taking a longer term view, we remain encouraged by the market available to us."
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
This comes at a critical time for Intel – the iconic chipmaker's stock is down nearly 55% in 2024 so far, which has drawn attention from rival Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), which is <a href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo">reportedly eyeing a takeover of Intel</a>.
While it is not clear if this will eventually materialize, it points to a weak phase that Intel is going through.
Three of the biggest chip makers – Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Intel, and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) – all have their respective data center business segments which have gained traction in 2023.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41328252/apples-iphone-16-powers-record-sales-in-q3-just-behind-samsung-in-global-market-share-battle">Apple&#8217;s iPhone 16 Powers Record Sales In Q3, Just Behind Samsung In Global Market Share Battle</a>
While Intel led in 2022, the company's data center revenue started declining in 2023, coinciding with Nvidia's rise. On the other hand, 2022 and 2023 were both lukewarm for AMD, but it started gathering pace in the fourth quarter of 2023.
Here's how Nvidia, Intel, and AMD's data center business has performed since 2022.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Period</td>
<td>Nvidia</td>
<td>Intel</td>
<td>AMD</td>
</tr>
<tr>
<td>Q1 2022</td>
<td>$3.8B</td>
<td>$6.1B</td>
<td>$1.3B</td>
</tr>
<tr>
<td>Q2 2022</td>
<td>$3.8B</td>
<td>$4.7B</td>
<td>$1.5B</td>
</tr>
<tr>
<td>Q3 2022</td>
<td>$3.8B</td>
<td>$4.4B</td>
<td>$1.6B</td>
</tr>
<tr>
<td>Q4 2022</td>
<td>$3.6B</td>
<td>$4.6B</td>
<td>$1.7B</td>
</tr>
<tr>
<td>Q1 2023</td>
<td>$4.3B</td>
<td>$3.7B</td>
<td>$1.3B</td>
</tr>
<tr>
<td>Q2 2023</td>
<td>$10.3B</td>
<td>$4.0B</td>
<td>$1.3B</td>
</tr>
<tr>
<td>Q3 2023</td>
<td>$14.5B</td>
<td>$3.8B</td>
<td>$1.6B</td>
</tr>
<tr>
<td>Q4 2023</td>
<td>$18.4B</td>
<td>$4B</td>
<td>$2.3B</td>
</tr>
<tr>
<td>Q1 2024</td>
<td>$22.6B</td>
<td>$3B</td>
<td>$2.3B</td>
</tr>
<tr>
<td>Q2 2024</td>
<td>$26.3B</td>
<td>$3B</td>
<td>$2.8B</td>
</tr>
<tr>
<td>Q3 2024</td>
<td>TBA</td>
<td>$3.3B</td>
<td>$3.5B</td>
</tr>
</tbody>
</table>
</figure>
Source: Nvidia, Intel, and AMD &#x7C; Nvidia's Q3 2024 results have not been announced yet.
Nvidia Rides AI Boost: Unsurprisingly, Nvidia's stock has also massively benefited from its dominance in AI chips – the Jensen Huang-led company has risen to the top, dethroning Apple on multiple occasions to become the world's most valuable company by market capitalization.
Nvidia's current market capitalization stands at $3.256 trillion, while Intel's is $92.73 billion and AMD's is $233.8 billion.
Gelsinger maintained an optimistic outlook, saying&nbsp;"We remain encouraged by the market available to us. There is a clear need for solutions with superior [total cost of ownership] based on open standards, and we are continuing to enhance the Gaudi value proposition."
For the quarter that just ended, Intel reported $13.28 billion in revenue, beating Street estimates of $13.02 billion.
Price Action: Intel's shares were up 6.8% in premarket trading on Friday at $22.98, according to Benzinga Pro data.
Nvidia's stock was up 1.1% at $134.27, while AMD stock was up 0.6% at $144.99.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/23/12/36199410/nvidias-ai-chips-eat-intels-lunch-heres-how-much-more-youd-have-made-if-you-invested-1-000-in-je">Nvidia&#8217;s AI Chips Eat Intel&#8217;s Lunch: Here&#8217;s How Much More You&#8217;d Have Made If You Invested $1,000 In Jensen Huang&#8217;s Company Instead Of Intel In 2023</a></li>
</ul>
Photos courtesy: Shutterstock

Equities

News

Markets

Tech

INTC

NVDA

QCOM

Intel Says It Won't Even Make $500M From Gaudi AI Chips In 2024 Despite Nvidia Minting Billions: CEO Gelsinger Says Uptake 'Slower Than We Anticipated'

Contracts

AAPL

Globalstar Amends Services Agreement With Apple To Launch Extended MSS Network With New Satellites And Infrastructure; Apple To Provide $1.1B Infrastructure Prepayment And Purchase 20% Stake For $400M; Agreement Includes Equity Repurchase Provisions, Performance-Based Service Fees, And Revised Debt Repayment Terms

Major technology firms are encountering a surprising trend where surpassing Wall Street estimates is not enough to satisfy investors. This has led to a decline in stock prices, despite positive earnings reports.
What Happened: Major technology companies are experiencing a paradox where surpassing Wall Street estimates is insufficient to satisfy investors.
On Thursday, Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported quarterly revenue exceeding expectations by $1 billion and an 11% increase in net income compared to the previous year.
Despite these impressive figures, Microsoft&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41654118/microsoft-stock-is-sliding-thursday-whats-going-on">shares fell by 6.1%</a> due to a conservative forecast for the upcoming quarter, marking its worst performance since October 26, 2022, CNBC <a href="https://www.cnbc.com/2024/11/01/cnbc-daily-open-big-tech-needs-to-go-beyond-beating-expectations-.html">reported</a> on Friday.
Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) faced similar investor reactions. Despite exceeding Wall Street estimates, the stock began sliding down during Friday pre-market due to investors concerns about weak guidance for December quarter sales. 
Even Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), which initially saw a nearly 3% rise in shares following its earnings report on Wednesday, experienced a <a href="https://www.benzinga.com/news/24/10/41663190/openai-rolls-out-chatgpt-search-google-shares-slide">1.9% decline on Thursday</a> after OpenAI announced rolling out of Chat GPT Search, a competition for Google Search.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41615718/cathie-woods-sky-high-vision-dumps-shares-of-cybercab-touting-tesla-for-this-evtol-play?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Sky-High Vision: Dumps Shares Of Cybercab Touting Tesla For This eVTOL Play</a>
Ross Mayfield, an investment strategist at Baird Private Wealth Management, commented on the situation, stating, "I think we're getting to the point where AI enthusiasm and potential is not enough. These companies are not quite delivering the growth that is priced into them." 
Why It Matters: The comment comes at a time when companies like Microsoft, Apple and Meta are banking on the AI buzz. <a href="https://www.benzinga.com/markets/equities/24/10/41643178/microsofts-ai-business-set-to-hit-10b-revenue-milestone-in-q2-satya-nadella-says-it-is-the-faste">Microsoft&#8217;s AI Business</a> is on track to surpass $10 billion in annual revenue, marking a significant milestone.
CEO Satya Nadella emphasized the rapid adoption of AI across Microsoft&#8217;s product portfolio, highlighting strong customer demand.
Jim Cramer noted that Alphabet&#8217;s plans to increase AI infrastructure investments next year <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41625103/jim-cramer-says-googles-ai-investment-next-year-should-be-fabulous-for-nvidia">could significantly benefit</a> NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). Alphabet&#8217;s recent earnings report revealed a 15% revenue increase, underscoring its strategic focus on technology advancements.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41642374/cathie-wood-shuffles-her-tech-deck-continues-dumping-tesla-and-palantir-stocks-up-on-amd-and-met?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Shuffles Her Tech Deck: Continues Dumping Tesla And Palantir, Stocks Up On AMD And Meta</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Images via Shutterstock, Edited via Canva

Analyst Color

General

GOOGL

MSFT

Apple, Microsoft Need To Do More Than Just Beating Wall Street Estimates, Says Analyst: 'AI Enthusiasm And Potential Is Not Enough"

<a href="https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/01/statement-from-president-joe-biden-on-the-october-2024-jobs-report/" title="https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/01/statement-from-president-joe-biden-on-the-october-2024-jobs-report/">https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/01/statement-from-president-joe-biden-on-the-october-2024-jobs-report/</a>

Macro Notification

Biden, Responding To October Jobs Data, Says Job Growth Is Expected To Rebound In November; Adds ' There's More Work To Do'; Says Hurricanes, Strike Activity Lowered Job Growth

On Thursday, ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) announced its plans to terminate the Phase 2 trial of masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer (mCRPC) naïve to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41669391/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined-with-enzalutami" rel="noreferrer noopener">second-generation antiandrogens</a>.
This decision was based on a protocol-specified interim review of the safety, PK, and efficacy data, which showed a much higher rate of PSA90 response in patients treated with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xtandi (enzalutamide) monotherapy (which is the standard of care for this patient population) than expected based on historical data.
In addition, there was no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent.
A futility analysis determined a low likelihood of meeting the prespecified primary endpoint of the study.
The combination of masofaniten plus enzalutamide was well-tolerated with no new safety signals and a safety profile similar to that seen in Phase 1 studies.
&#8220;We made the difficult decision to terminate this Phase 2 study following the interim analysis because we concluded that the emerging efficacy profile of masofaniten combined with enzalutamide would not likely meet the primary endpoint of the study, nor our internal requirements for a prostate cancer therapy candidate,&#8221; said&nbsp;David Parkinson, President, and CEO.
As part of the effort to focus its resources, ESSA is also planning to terminate the other remaining company-sponsored and investigator-sponsored clinical studies evaluating masofaniten either as a monotherapy or in combination <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40862721/essa-pharma-presents-updated-phase-12-masofaniten-epi-7386-clinical-data-at-the-2024-esmo-congress" rel="noreferrer noopener">with other agents</a>.
As of&nbsp;September 30, 2024, the company had available cash reserves and short-term investments of&nbsp;$126.8 million&nbsp;and net working capital of&nbsp;$124.3 million.
In September, ESSA Pharma announced the presentation of updated dose escalation data from its Phase 1/2 study of masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 European Society for Medical Oncology (ESMO) Congress.
Across all dose cohorts, 88% of patients (14 of 16) achieved PSA50, 88% of patients (14 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 days, and 63% of patients (10 of 16) achieved PSA &lt;0.2ng/mL.
Price Action: EPIX stock was down 69.80% at $1.57 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41685490/nvidias-run-ai-acquisition-draws-european-regulatory-scrutiny-on-competition-concerns" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Run: ai Acquisition Draws European Regulatory Scrutiny On Competition Concerns</a></li>
</ul>

Biotech

Health Care

Movers

EPIX

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) shares are trading lower after the company reported worse-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41679038/lyondellbasell-reports-third-quarter-2024-earnings" rel="noreferrer noopener">third-quarter results</a>.
LYB reported revenues of $10.332 billion, down 2.8% year over year and missing the consensus of $10.601 billion.
Adjusted EBITDA stood at $1.21 billion (-14.1% Y/Y), and the margin contracted by 154 bps to 11.7%. Adjusted EPS stood at $1.88, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">below the consensus of $1.98.</a>
North American polyethylene margins rose due to lower ethane and gas costs, with demand up over 7% year-to-date. High cracker operating rates boosted third-quarter&nbsp;ethylene volumes, while Europe and Asia margins benefited from lower feedstock costs.
LyondellBasell generated $670 million operating cash flow in the third quarter, with 80% cash conversion over 12 months.
The company invested $368 million in capital expenditures, returned $479 million to shareholders, and held $2.6 billion in cash with $7.3 billion in liquidity.
LyondellBasell&#8217;s CEO, Peter Vanacker, announced that the company started construction on its new MoReTec-1 facility in Germany, a key step toward a sustainable future.
Q4 Outlook: LyondellBasell anticipates softer demand in the fourth quarter due to seasonality, with sequentially higher natural gas and ethane feedstock&nbsp;costs likely impacting North American integrated&nbsp;polyolefins margins.
Operating rates are projected at 85% for North American O&amp;P assets, 60% for European O&amp;P, and 75% for I&amp;D assets, with easing interest rates expected to boost durable goods demand in 2025.
&#8220;Despite challenging global macroeconomic conditions, our strong North American operations allowed us to capitalize on favorable ethylene margins in the region,&#8221; said Vanacker.
Price Action: LYB shares traded lower by 0.98% at $86.00 premarket at the last check Friday.

Earnings

Guidance

LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4

Oppenheimer analyst Edward Yang maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Outperform and raises the price target from $260 to $275.

Price Target

Analyst Ratings

ONTO

Oppenheimer Maintains Outperform on Onto Innovation, Raises Price Target to $275

Oppenheimer analyst Jed Kelly maintains LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) with a Outperform and raises the price target from $65 to $70.

TREE

Oppenheimer Maintains Outperform on LendingTree, Raises Price Target to $70

Keybanc analyst Alex Markgraff maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and raises the price target from $515 to $580.

Keybanc Maintains Overweight on Mastercard, Raises Price Target to $580

Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $560 to $646.

ARGX

Oppenheimer Maintains Outperform on argenx, Raises Price Target to $646

Oppenheimer analyst Michael Phillips maintains Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Outperform and raises the price target from $165 to $177.

Oppenheimer Maintains Outperform on Hanover Insurance Gr, Raises Price Target to $177

JP Morgan analyst Doug Anmuth maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Neutral and lowers the price target from $60 to $58.

EBAY

JP Morgan Maintains Neutral on eBay, Lowers Price Target to $58

The U.S. Securities and Exchange Commission (SEC) announced Thursday that it has charged two affiliates of JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) in five separate enforcement actions resulting in penalties and voluntary payments to investors of <a href="https://www.benzinga.com/markets/equities/24/10/41590849/jpmorgan-sues-customers-over-infinite-money-glitch-that-went-viral-on-tiktok-theyre-held-account">more than $151 million. </a>
The Details: The SEC<a href="https://www.sec.gov/newsroom/press-releases/2024-178"> charged</a> J.P. Morgan Securities LLC and J.P. Morgan Investment Management Inc. in five separate enforcement actions. Among the violations the agency flagged: misleading disclosures to investors, breach of fiduciary duty, prohibited joint transactions and principal trades, and failures to make recommendations in the best interest of customers. 
The JPMorgan affiliates agreed to pay more than $151 million in combined civil penalties and voluntary payments to investors to resolve the actions. The firm did not admit nor deny the findings in the SEC's orders. 
Read Next: <a href="https://www.benzinga.com/markets/asia/24/10/41656452/alibabas-strong-singles-day-sales-kickoff-hints-at-china-consumer-rebound">Alibaba&#8217;s Strong Singles&#8217; Day Sales Kickoff Hints At China Consumer Rebound</a>
"JPMorgan's conduct across multiple business lines violated various laws designed to protect investors from the risks of self-dealing and conflicts of interest," said Sanjay Wadhwa, Acting Director of the SEC's Division of Enforcement. 
"With today's settlements, which include multiple self-reports and large voluntary payments to harmed investors, JP Morgan is being held accountable for its regulatory failures," Wadhwa added.&nbsp;
One of the enforcement actions against J.P. Morgan Securities found that the firm made misleading disclosures to customers who invested in its Conduit private funds products which resulted in complaints from clients after the value of certain shares declined significantly.  
As part of the resolution, J.P. Morgan Securities agreed to make a voluntary payment of $90 million to more than 1,500 Conduit investor accounts. It also agreed to pay a civil penalty of $10 million, which will also be distributed to Conduit investors. 
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, JPMorgan shares are up 0.09 % at $222.13 at the time of publication Friday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41489239/bank-of-america-ceo-cautions-fed-not-to-go-too-fast-or-too-slow-on-interest-rate-cuts">Bank Of America CEO Cautions Fed Not To &#8216;Go Too Fast Or Too Slow&#8217; On Interest Rate Cuts</a></li>
</ul>
Image: Shutterstock&nbsp;

Large Cap

Legal

JPMorgan To Pay Investors $151 Million After SEC Flags 'Various Law Violations'

Oppenheimer analyst Ittai Kidron maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Outperform and raises the price target from $230 to $270.

TEAM

Oppenheimer Maintains Outperform on Atlassian, Raises Price Target to $270

JP Morgan analyst Tien-Tsin Huang maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and lowers the price target from $593 to $580.

JP Morgan Maintains Overweight on Mastercard, Lowers Price Target to $580

Keybanc analyst Justin Patterson maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and lowers the price target from $90 to $85.

UBER

Keybanc Maintains Overweight on Uber Technologies, Lowers Price Target to $85

Oppenheimer analyst Jason Helfstein maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and raises the price target from $220 to $230.

AMZN

Oppenheimer Maintains Outperform on Amazon.com, Raises Price Target to $230

<ul>
<li>AMZN</li>
<li>INTC</li>
<li>NVDA</li>
<li>AAPL</li>
<li>DJT</li>
<li>SMCI</li>
<li>LOT</li>
<li>AMD</li>
<li>MSFT</li>
<li>META</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Comments

NMB Finl

Vendite allo scoperto

NMB Finl (OTC:NMBF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO